Abstract:
:Despite the widespread use of trastuzumab in the management of patients with HER2-overexpressing metastatic breast cancer, its optimal duration of administration is unknown. We retrospectively reviewed the medical records of 80 such patients who received trastuzumab monotherapy or combination chemotherapy beyond disease progression in order to register their clinical course. Median age of the patients was 54 years. Ninety-one percent had 3+ HER2 overexpression and 9% had 2+ HER2 overexpression. Fifty-six percent of patients had previously been treated with chemotherapy for advanced disease. The most commonly used combinations in first- and second-line treatments were trastuzumab with paclitaxel and trastuzumab with vinorelbine, respectively. In total, 32 responses were observed, most of them during the second or third line of treatment. Severe toxicities frequently seen (in = 5% of patients) were neutropenia (25%), thrombocytopenia (11.5%), infection (10%), peripheral neuropathy (9%), nausea/vomiting (6%), stomatitis (6%), diarrhea (6%), constipation (6%), edema (6%), and myalgias/arthralgias (5%). Median survival from diagnosis of advanced disease was 43.4 months (range, 6.4-91.7+), whereas median survival from disease progression after trastuzumab administration was 22.2 months (range, 0.01-32.9+). In conclusion, this retrospective analysis suggests that continuation of trastuzumab beyond disease progression in patients with HER2-overexpressing metastatic breast cancer is feasible and safe. Randomized studies are warranted.
journal_name
Clin Breast Cancerjournal_title
Clinical breast cancerauthors
Fountzilas G,Razis E,Tsavdaridis D,Karina M,Labropoulos S,Christodoulou C,Mavroudis D,Gogas H,Georgoulias V,Skarlos Ddoi
10.3816/cbc.2003.n.017keywords:
subject
Has Abstractpub_date
2003-06-01 00:00:00pages
120-5issue
2eissn
1526-8209issn
1938-0666pii
S1526-8209(11)70452-9journal_volume
4pub_type
杂志文章,多中心研究abstract:BACKGROUND:Nanoparticle albumin-bound paclitaxel (nab-P) and bevacizumab have each demonstrated efficacy in patients with MBC. This trial was designed to further develop nab-P by evaluating its efficacy and safety using every 3 weeks (q3w), every 2 weeks (q2w), or weekly scheduling in combination with bevacizumab as fi...
journal_title:Clinical breast cancer
pub_type: 杂志文章,随机对照试验
doi:10.1016/j.clbc.2013.02.008
更新日期:2013-08-01 00:00:00
abstract:BACKGROUND:Two large randomized trials, CALGB 9343 and PRIME II, support omission of radiotherapy after breast conserving surgery (BCS) in elderly women with favorable-risk early stage breast cancer intending to take endocrine therapy. However, patients with grade 3 histology were underrepresented on these trials. We h...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2020.05.007
更新日期:2020-12-01 00:00:00
abstract:BACKGROUND:Recent observational studies are concerning because they document rising mastectomy rates coinciding with more than a dozen reports that lumpectomy has better overall survival (OS) than mastectomy. Our aim was to determine if there were differences in OS of matched breast cancer patients undergoing lumpectom...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2019.02.006
更新日期:2019-06-01 00:00:00
abstract::The management of metastatic breast cancer is changing as a consequence of extraordinary discoveries in cancer research and the development of more advanced diagnostic technologies. Although traditional chemotherapeutics such as anthracyclines and taxanes still represent the mainstay of treatment for this disease, new...
journal_title:Clinical breast cancer
pub_type: 杂志文章,评审
doi:10.3816/CBC.2001.n.002
更新日期:2001-01-01 00:00:00
abstract::Breast carcinoma in men is rare and comprises approximately 1% of all breast cancer cases. In contrast to the increase in the detection rate of ductal carcinoma in situ (DCIS) in women resulting from the wide use of screening mammography programs, the rate of male DCIS is still small and represents approximately 5% of...
journal_title:Clinical breast cancer
pub_type: 杂志文章,评审
doi:10.3816/CBC.2005.n.033
更新日期:2005-10-01 00:00:00
abstract:INTRODUCTION:The increment of breast cancer screening coverage should lead to an increase in the proportion of early tumors diagnosed and the decrease of the cancer-related mortality. However, the effectiveness of opportunistic mammography screening is not well documented for public health systems in middle-income coun...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2019.04.014
更新日期:2019-12-01 00:00:00
abstract::Traditionally in the treatment of primary breast cancer, axillary lymph node dissection (ALND) plays an important role. However, a substantial and increasing percentage of patients appear to have no nodal involvement and have been subjected to ALND unnecessarily. The first reason to perform an ALND is axillary nodal s...
journal_title:Clinical breast cancer
pub_type: 杂志文章,评审
doi:10.3816/cbc.2002.n.034
更新日期:2002-12-01 00:00:00
abstract:BACKGROUND:Following treatment for breast cancer, many young women are interested in having a child. There are few data available regarding actual fertility and menopausal outcomes in young breast cancer survivors. We evaluated these outcomes among young breast cancer survivors in collaboration with the Young Survival ...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.3816/CBC.2008.n.004
更新日期:2008-02-01 00:00:00
abstract:AIM:Our study was to investigate the heterogeneity of estrogen receptor (ER) expression among tumor sites by using fluorine-18 ((18)F) fluoroestradiol (FES) positron-emission tomography-computed tomography (PET-CT) imaging. METHODS:Thirty-two breast cancer patients underwent both (18)F-FES and (18)F fluorodeoxyglucose...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2013.02.012
更新日期:2013-10-01 00:00:00
abstract:BACKGROUND:Nipple-sparing mastectomies (NSMs) preserve the intact nipple, including nipple duct orifices. Retained orifices might remain patent and communicate with the underlying reconstruction. We report the incidence and outcomes of nipple discharge after NSM in pregnant and nonpregnant women. PATIENTS AND METHODS:...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2019.03.003
更新日期:2019-08-01 00:00:00
abstract:BACKGROUND:Triple-negative breast cancer (TNBC) is an aggressive disease without established targeted treatment options for patients with metastatic disease. This study was undertaken to evaluate potentially actionable biomarkers in a large cohort of TNBC and compare them with non-TNBCs. MATERIALS AND METHODS:We evalu...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2015.04.008
更新日期:2015-12-01 00:00:00
abstract:BACKGROUND:We examined tumor genotype characteristics of human epidermal growth factor receptor 2 (HER2)-positive relapsed (R-) and de novo (dn-) metastatic breast cancer (MBC) in trastuzumab-treated patients who were previously not exposed to this agent. MATERIALS AND METHODS:We analyzed genotypes obtained upon deep ...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2018.10.014
更新日期:2019-04-01 00:00:00
abstract:BACKGROUND:Several studies conducted in developed countries introduced diet and physical inactivity as major risk factors for several types of cancers. However, the impact of diet and physical inactivity on the risk of breast cancer (BC) is understudied, and the limited findings are controversial. In addition, no or li...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2018.10.011
更新日期:2019-02-01 00:00:00
abstract::Overexpression of the p185/HER2 protein is seen in 20%-25% of primary breast cancers and is associated with poor prognosis. Recent phase II and III clinical trials demonstrate that trastuzumab is active against breast tumors, both as a single agent and in combination with chemotherapy. In patients with HER2-overexpres...
journal_title:Clinical breast cancer
pub_type: 杂志文章,评审
doi:10.3816/cbc.2001.s.003
更新日期:2001-10-01 00:00:00
abstract:BACKGROUND:The purpose of this study was to investigate whether combining pembrolizumab with palliative radiation therapy (RT) improves outcomes in patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC). PATIENTS AND METHODS:Eligible patients had HR+/human epidermal growth factor receptor 2-negat...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2020.01.012
更新日期:2020-06-01 00:00:00
abstract:BACKGROUND:The inexpensive prediction of the characteristics of BRCA-mutated breast cancer as "BRCAness" using the somatic cells of patients with breast cancer could be useful for developing a therapeutic strategy. Our objective was to correlate BRCAness with the clinicopathologic features, including a family history (...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2018.05.008
更新日期:2018-10-01 00:00:00
abstract:BACKGROUND:Activation of the JAK/STAT pathway is common in triple-negative breast cancer (TNBC) and affects the expression of genes controlling immune signaling. A subset of TNBC cases will have somatic amplification of chromosome 9p24.1, encoding PD-L1, PD-L2, and JAK2, which has been associated with decreased surviva...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2018.05.006
更新日期:2018-10-01 00:00:00
abstract::Prostate adenocarcinoma can manifest as a fairly indolent tumor or as a very aggressive cancer with significant invasive and metastatic potential. Common metastatic sites include bone, liver, lymph nodes, and adrenal glands. Dermatologic manifestations are rare. We present a case of a man who presented with breast ski...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.3816/CBC.2010.n.013
更新日期:2010-02-01 00:00:00
abstract::Kaposiform hemangioendothelioma (KHE) is a locally aggressive vascular tumor that usually occurs in infants. It is commonly associated with Kasabach-Merritt syndrome and lymphangiomatosis. It generally originates on the skin, later affecting deeper tissue by infiltrative growth. Although visceral involvement is very u...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2011.03.008
更新日期:2011-04-01 00:00:00
abstract:BACKGROUND:Seromas constitute a common complication following surgery for breast cancer, and closed drainage is used routinely to reduce its incidence. The aim of this study was to evaluate the influence of number of drains on patient discomfort, seroma formation, and hospital stay during the immediate postoperative pe...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.3816/CBC.2009.n.041
更新日期:2009-11-01 00:00:00
abstract:INTRODUCTION:Implant-sparing mastectomy (ISM) is a skin-sparing mastectomy that preserves a retropectoral implant and potentially eliminates the need for tissue expansion or complex reconstruction. This study aimed to determine oncologic and surgical outcomes and reconstructive patterns in patients undergoing ISM. PAT...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2019.08.007
更新日期:2020-02-01 00:00:00
abstract::Chemotherapeutic agents that disrupt the assembly or disassembly of microtubules, including paclitaxel and docetaxel, are among the most commonly prescribed anticancer therapies. However, the utility of taxane-based therapy is limited principally by problems with formulation, slow administration, cumulative neurotoxic...
journal_title:Clinical breast cancer
pub_type: 杂志文章,评审
doi:10.3816/cbc.2008.s.001
更新日期:2008-03-01 00:00:00
abstract:INTRODUCTION:Ensuring guideline-concordant cancer care is a Department of Veterans Affairs (VA) priority, especially as the number of breast cancer patients at VA medical centers (VAMCs) grows. We assessed the utilization and clinical impact of the 21-gene Recurrence Score test, which predicts 10-year risk of breast ca...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2017.11.018
更新日期:2018-04-01 00:00:00
abstract:BACKGROUND:The purpose of this study was to assess the activity and safety of the combination of vinorelbine (VNR) and capecitabine (CAP) as first-line treatment in HER2-negative (HER(-)) metastatic breast cancer (MBC). PATIENTS AND METHODS:Patients (42) enrolled in trial A received intravenous (i.v.) VNR 25 mg/m2 on ...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2011.11.001
更新日期:2012-02-01 00:00:00
abstract:INTRODUCTION:Emerging research suggests a substantially greater prevalence of the adverse triple-negative (TN) subtype (human epidermal growth factor receptor [HER]2(-), estrogen receptor [ER](-), and progesterone receptor [PR])(-)) among black patients with breast cancer. No reports however have been generated from a ...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2011.04.004
更新日期:2011-10-01 00:00:00
abstract:PURPOSE:To determine the overall performance of contrast-enhanced ultrasound (CEUS) in differentiating between benign and malignant breast lesions and in predicting the pathologic response to neoadjuvant chemotherapy (NAC) in patients with breast cancer (BC). MATERIALS AND METHODS:Articles published up to April 2019 w...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2020.03.002
更新日期:2020-08-01 00:00:00
abstract::In a review of current information on aromatase inhibitors (AIs) and their use in breast cancer treatment and prevention, published reports were obtained through a Medline search. Tamoxifen, a selective estrogen receptor modulator, is approved for use in metastatic breast cancer (MBC), the adjuvant treatment of breast...
journal_title:Clinical breast cancer
pub_type: 杂志文章,评审
doi:10.3816/CBC.2005.n.006
更新日期:2005-04-01 00:00:00
abstract::Hot flashes are the most prominent side effect of tamoxifen, the most frequently prescribed antitumor agent in the world. Little detailed information is available to predict who will develop hot flashes on tamoxifen, to describe the natural history of these hot flashes, and/or to predict who will request therapy for s...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.3816/cbc.2000.n.004
更新日期:2000-04-01 00:00:00
abstract::Involvement of axillary lymph nodes is an important prognostic factor in relationship to the management of breast cancer. However, the use of neoadjuvant systemic therapy is widespread in the treatment of positive axilla and such treatment leads to downstaging of axillary disease. Hence, the role of targeted axillary ...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2018.06.001
更新日期:2018-10-01 00:00:00
abstract:INTRODUCTION:Unwanted clinical variation is common across the United States health care system and is particularly vexing in oncology owing to the complexity, morbidity, and high cost of the disease. Efforts to standardize care including guidelines and continuing medical education have had only limited impact. Disease-...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2018.12.010
更新日期:2019-04-01 00:00:00